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Alpha-1 antitrypsin deficiency (AATD) is the only well-recognized genetic disorder associated with an increased risk of emphysema and COPD.[@b1-copd-12-2257] Identifying AATD allows genetic counseling and the chance to offer specific augmentation therapy to slow emphysema progression. Despite specific recommendations from the World Health Organization, American Thoracic Society and European Respiratory Society to screen all patients with COPD and other at-risk conditions,[@b2-copd-12-2257]--[@b4-copd-12-2257] testing rates are low (\<15%).[@b5-copd-12-2257]

We conducted a project to improve AATD screening at the Miami VA Medical Center using the pulmonary function test (PFT) laboratory. We instructed the PFT personnel to perform reflex testing on all patients with pre-bronchodilator airflow obstruction (forced expiratory volume in 1 second/forced vital capacity \<70%) and then evaluated if the screening was appropriate according to guidelines. Trained PFT personnel explained AATD disease to patients and provided them with an informational brochure. After obtaining verbal consent, AATD screening was performed using dried blood spot kits provided by the Alpha-1 Foundation as part of the Florida Screening Program (noncommercial).[@b6-copd-12-2257] The PFT lab director was the responsible physician of record, in charge of discussing positive results to patients and documenting results in the electronic medical record. The Miami Veterans Affairs Medical Center Institutional Review Board approved the protocol as a quality improvement project.

Since launching the program, testing rates in our center had a 15-fold increase from baseline. In 4 years, the PFT laboratory performed 78% of the 1,021 tests ordered in our institution, leading to a decrease in the number of tests done by the pulmonary clinic ([Figure 1](#f1-copd-12-2257){ref-type="fig"}). Review of the 799 cases tested by the PFT laboratory found that 671 (83%) had an appropriate clinical indication for screening according to guidelines.[@b3-copd-12-2257],[@b4-copd-12-2257] The remaining subjects tested had mostly asthma (9.6%), other reasons for airflow obstruction such as sarcoidosis (2.2%) or did not have airflow obstruction (5%). Importantly, the COPD patients tested by the PFT laboratory were more likely to be active smokers with significantly better lung function compared with those tested at the pulmonary clinic ([Table 1](#t1-copd-12-2257){ref-type="table"}).

Our experience highlights the importance of partnering with PFT laboratory personnel to improve AATD testing rates. Respiratory therapists are exposed to a higher number of pulmonary patients at risk for AATD than pulmonologists and can improve detection of affected individuals in the course of their routine practices.[@b7-copd-12-2257] Continued education efforts and focusing on testing subjects with persistent airflow obstruction after bronchodilator testing could further reduce unnecessary testing rates. We conclude that reflex AATD testing by PFT personnel is an effective way to comprehensively and appropriately test subjects at risk. Furthermore, this strategy appears to identify a population that is more amenable to benefit from detection at an earlier disease stage.
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###### 

Characteristics of subjects with confirmed COPD tested at the PFT laboratory and pulmonary clinics

  Characteristics   All         Tested at the PFT laboratory   Tested at the pulmonary clinics   *P*-value
  ----------------- ----------- ------------------------------ --------------------------------- -----------
  n                 831         642                            189                               
  Age, years        66.8±8.2    66.8±8.3                       66.5±7.7                          0.76
  Active smokers    43.90%      47.04%                         33.33%                            0.004
  FEV~1~ % post     56.1±19.1   58.1±18.6                      49.0±18.7                         \<0.001
  FEV~1~/FVC post   53.4±13.1   54.3±12.8                      50.1±13.7                         \<0.001
  Emphysema on CT   76.99%      76.20%                         79.53%                            0.36
  Genotype                                                                                       
   MM               90.30%      90.78%                         88.89%                            0.87
   MS               5.90%       5.47%                          7.41%                             
   MZ               2.10%       2.19%                          2.12%                             
   SZ               0.36%       0.31%                          0.53%                             
   ZZ               0%          0%                             0%                                
   Other            1.20%       1.25%                          1.06%                             

**Abbreviations:** CT, computed tomography; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; PFT, pulmonary function test.
